Revestive (teduglutide)

pCPA File Number: 21174
Negotiation Status:
Concluded with an LOI
Indication(s):
Short Bowel Syndrome (SBS)
Sponsor/Manufacturer:
Shire Pharma Canada ULC
CDA-AMC Project Number:
SR0606-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded: